Kiniksa Pharmaceuticals to Present at 2021 Cantor Fitzgerald Virtual Global Healthcare Conference

Rhea-AI Summary

Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced its participation in the 2021 Cantor Fitzgerald Virtual Global Healthcare Conference. The event will take place on Tuesday, September 28, 2021, at 10:40 a.m. Eastern Time. Interested parties can access the live webcast via the Investors & Media section of Kiniksa's website, with a replay available approximately 48 hours post-event. Kiniksa focuses on developing therapeutic medicines for serious diseases, with its portfolio including ARCALYST®, mavrilimumab, vixarelimab, and KPL-404, targeting significant unmet medical needs.

News Market Reaction – KNSA

-1.78%

-1.78% Session move

In the trading session that priced this news, KNSA declined 1.78%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

HAMILTON, Bermuda, Sept. 21, 2021 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will present at the 2021 Cantor Fitzgerald Virtual Global Healthcare Conference on Tuesday, September 28, 2021 at 10:40 a.m. Eastern Time.

A live webcast of Kiniksa’s presentation will be accessible through the Investors & Media section of the company’s website at www.kiniksa.com. A replay of the webcast will also be available on Kiniksa’s website within approximately 48 hours after the event.

About Kiniksa
Kiniksa is a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Kiniksa’s portfolio of assets, ARCALYST^® (rilonacept), mavrilimumab, vixarelimab and KPL-404, are based on strong biologic rationale or validated mechanisms, target underserved conditions and offer the potential for differentiation. These assets are designed to modulate immunological pathways across a spectrum of diseases. For more information, please visit www.kiniksa.com.

ARCALYST^® is a registered trademark of Regeneron Pharmaceuticals, Inc.

Every Second Counts!™

Kiniksa Investor and Media Contact
Rachel Frank
(339) 970-9437
rfrank@kiniksa.com

FAQ

What is the date and time of Kiniksa's presentation at the Cantor Fitzgerald Conference?

Kiniksa's presentation will take place on September 28, 2021, at 10:40 a.m. Eastern Time.

Where can I watch Kiniksa's presentation from the conference?

The live webcast of Kiniksa's presentation will be available on their website in the Investors & Media section.

Will there be a replay of Kiniksa's presentation?

Yes, a replay of the webcast will be available on Kiniksa's website approximately 48 hours after the event.

What are some products in Kiniksa's portfolio?

Kiniksa's portfolio includes ARCALYST®, mavrilimumab, vixarelimab, and KPL-404, which target serious diseases with unmet medical needs.

What is Kiniksa Pharmaceuticals focused on?

Kiniksa Pharmaceuticals is focused on discovering and developing therapeutic medicines for patients with debilitating diseases.